J 2022

Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study

BRETSCHNEIDER, Maxi Pia, Jan KLÁSEK, Martina KARBANOVÁ, Patrick TIMPEL, Sandra HERRMANN et. al.

Základní údaje

Originální název

Impact of a Digital Lifestyle Intervention on Diabetes Self-Management: A Pilot Study

Autoři

BRETSCHNEIDER, Maxi Pia (276 Německo), Jan KLÁSEK (203 Česká republika), Martina KARBANOVÁ (203 Česká republika, domácí), Patrick TIMPEL (276 Německo), Sandra HERRMANN (276 Německo) a Peter E. H. SCHWARZ (276 Německo)

Vydání

Nutrients, Basel, MDPI, 2022, 2072-6643

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30304 Public and environmental health

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 5.900

Kód RIV

RIV/00216224:14110/22:00125808

Organizační jednotka

Lékařská fakulta

UT WoS

000794653000001

Klíčová slova anglicky

diabetes mellitus type 2; self-management; digital health; HbA1c; lifestyle intervention; digital intervention; mHealth

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 23. 1. 2023 10:56, Mgr. Tereza Miškechová

Anotace

V originále

The aim of this study was to provide preliminary evidence on the impact of the digital health application Vitadio on improving glycemic control in patients with type 2 diabetes mellitus. This was a 3-month, prospective, multicenter, open-label trial with an intraindividual control group. Participants received a digital lifestyle intervention. HbA1c levels were observed at 3 time points: retrospectively, at 3 months before app use; at baseline, at the start of usage; and 3 months after the start of use. In addition, changes in other metabolic parameters (fasting glucose, body weight, and waist circumference), patient reported outcomes (quality of life, self-efficacy, and depression), and data generated within the app (frequency of use, steps, and photos of meals) were evaluated. Repeated measures analysis of variance with the Bonferroni correction was used to assess the overall difference in HbA1c values between the intervention and the intraindividual control group, with p < 0.05 considered significant. Participants (n = 42) were 57 +/- 7.4 years old, 55% male, and with a mean baseline HbA1c of 7.9 +/- 1.0%. An average HbA1c reduction of -0.9 +/- 1.1% (p < 0.001) was achieved. The digital health application was effective in significantly reducing body weight (-4.3 +/- 4.5 kg), body mass index (-1.4 +/- 1.5 kg/m(2)), waist circumference (-5.7 +/- 15 cm), and fasting glucose (-0.6 +/- 1.3 mmol/L). The digital therapy achieved a clinically meaningful and significant HbA1c reduction as well as a positive effect on metabolic parameters. These results provide preliminary evidence that Vitadio may be effective in supporting patient diabetes management by motivating patients to adopt healthier lifestyles and improving their self-management.